New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
World Federation of hemphilia (WFH) shared on X about a recent article by Davide Matino et al, published in Haemophilia Journal:
”A new Canadian study explores outcomes for people with hemophilia A (12+) who switched to a longer-acting treatment, looking at bleeding, quality of life, infusion frequency, and treatment satisfaction.”
Title: Canadian Clinical Experience on Switching From Standard Half-life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half-life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada
Authors: Davide Matino, Anthony K. C. Chan, Kay Decker, Emma Iserman, Andrea N. Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Read the Full Article on Haemophilia Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 21:27Satish Bondala: Blood Bank and Transfusion Services – The Lifeline of Hospitals
-
Apr 15, 2026, 21:26Tareq Abadl: Understanding Thalassemia – Breaking the ‘Ordinary Anemia’ Myth
-
Apr 15, 2026, 21:24Wolfgang Miesbach: Key Message from John Semple on Platelets as Immune Cells in ITP
-
Apr 15, 2026, 21:22Manuel Gutiérrez de Ravé: Promotion to Real-World Evidence Scientist at Terumo Blood and Cell Technologies
-
Apr 15, 2026, 18:45Elias Lee: Acute PE from Subclavian VT – CT Scan Diagnosis, Radiology Interpretation, and Emergency Imaging Insights
-
Apr 15, 2026, 17:30Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health
-
Apr 15, 2026, 17:01Emmanuel J Favaloro: A Practical Approach to Inherited and Acquired Coagulation Disorders
-
Apr 15, 2026, 16:55Chokri Ben Lamine: VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
-
Apr 15, 2026, 16:54Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory